EP1294706A1 - Procede permettant la lactonisation pour la production de simvastatine - Google Patents

Procede permettant la lactonisation pour la production de simvastatine

Info

Publication number
EP1294706A1
EP1294706A1 EP02749274A EP02749274A EP1294706A1 EP 1294706 A1 EP1294706 A1 EP 1294706A1 EP 02749274 A EP02749274 A EP 02749274A EP 02749274 A EP02749274 A EP 02749274A EP 1294706 A1 EP1294706 A1 EP 1294706A1
Authority
EP
European Patent Office
Prior art keywords
simvastatin
lactonization
xylenes
reaction
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02749274A
Other languages
German (de)
English (en)
Inventor
Dandala c/o Aurobindo Pharma Limited RAMESH
Sebastian c/o Aurobindo Pharma Limited SONNY
J. M. R. Aurobindo Pharma Limited SANAPUREDDY
S. Aurobindo Pharma Limited MEENAKSHISUNDERAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of EP1294706A1 publication Critical patent/EP1294706A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones

Definitions

  • This invention relates to a process for lactonization to produce simvastatin
  • Lovastatin, simvastatin, pravastatin, atorvastat ⁇ n and mevastatin are well known potent antihypercholesterolemic agents that function by limiting cholesterol biosynthesis by inhibiting the enzyme, HMG-CoA reductase.
  • This class of compounds referred to generally as statins are produced either by natural fermentation process or through semi-synthetic and totally synthetic means thereof.
  • Two of the most popular compounds in this therapeutic category are simvastatin and atorvastatin.
  • the former is one of the most prescribed drugs in the treatment of primary hypercholesterolemia with minimum side effects and well established safety profile.
  • the use of highly pure simvastatin is exceedingly desirable in preparation of a pharmaceutical form as it would avoid accumulation of impurities during prolonged usage and would reduce the possible side effects during medical treatment.
  • dimer impurity is difficult to separate from the desired lactone even with repeated crystallization.
  • the presence of dimer lowers the purity of the simvastatin product.
  • US Patent 4.916,239 describes another process where the lactonization reaction has been earned out by treating hydroxyacid ammonium salt in a mixture of acetic add and water, and in the presence of a strong acid catalyst. This process requires gradual addition of water in several lots to effect crystallization of the lactonized product from the reaction medium to shift the equilibrium to the lactone side and this drives the lactonization to completion. This process is not amenable to industrial scale due to effluent generation and low purity of simvastatin product even though dimer content obtained is reported to be less than 0.2%.
  • the reaction is to be carried out essentially for a period of 5-7 hours and extensive water washing of the product is required to remove traces of acetic acid.
  • the aim of the present invention is to provide a highly efficient method for lactonization to produce simvastatin of greater than 99% purity in high yield.
  • An example where simvastatin of greater than 99.5% purity has been achieved is cited in WO 99/42601 wherein the product was purified by successive crystallizations from aqueous acetone and from ethyl acetate.
  • Z is H or NFL, in an organic solvent elected from xylenes, ethylbenzene and mixtures thereof at a temperature of 130 to 140° C.
  • the organic solvent is preferably xylenes and Z is NH 4 Detailed Description of the Invention:
  • the instant invention relates to a novel process of lactonizing hydroxyacid ammonium salt in xylenes at reflux temperature.
  • the lactonization reaction is efficiently accomplished within 30 minutes in pres «ence of an antioxident under a constant purge of nitrogen.
  • the level of dimer impurity in the rseaction mixture under the present cyclization conditions is restricted to less than 0.4% and isolation of the simvastatin lactone from the reaction mass reduces it further to less than 0.2% as recommended in Pharma Europa, Vol. 10, No. 3, September, 1998.
  • This kind of smooth reaction and the product stability at high temperature were not anticipated and this observation constitutes an important part of the present invention.
  • the amount of xylenes is 20 to 50 parts by volume per part of the starting material. However, preferably 25 parts by volume is enough to carryout the lactonization recation.
  • the said reaction can be conducted in different solvents having boiling range above 110° C such as ethylbenzene. The reaction is carried out at 110 to 140° C but preferably at 130-140° C.
  • an antioxident is added and nitrogen is bubbled through the reaction mass. Suitable antioxidents include butylated hydroxytoluene and butylated hydroxyanisole.
  • Product is isolated by distilling off xylenes and crystallization from cyclohexene to give simvastatin of greater than 99% purity. This can be further re-crystaliized from methanol and water to consistently attain more than 99.4% purity.
  • the lactonization reaction is conducted by heating simvastatin ammonium salt in xylenes at 135-140° C for 30 minutes.
  • simvastatin ammonium salt in xylenes at 135-140° C for 30 minutes.
  • extended heating in xylenes gives dimer to the extent of 0.65% against 1.2% in toluene.
  • the major advantages realized in the present lactonization conditions as compared to the prior art are increased process productivity and product purity.
  • the reaction period is typically 30 minutes that demonstrates a greater efficiency. Xylenes are fully recovered and recycled in the process and no aqueous effluent is generated.
  • Simvastatin (83 g., 0.198 moles) was dissolved in methanol (830 ml.) at 10-15° C and DM water (830 ml.) was added slowly over a period of one hour. The product slurry was cooled to 3-5° C and was maintained at this temperature for 1 hour. The product was then filtered and washed with chilled methanol/water mixture (1:1 v/v, 50 ml.) and dried in vacuo at 50-55° C to obtain simvastatin (80 g., 96.4%) in pharmaceutically accepted 99.55% HPLC purity. The level of dimer was ⁇ 0.2% (0.18%).
  • Hydroxyadd a ⁇ nmonium salt of Formula II required in lactonization is prepared by the following procedure:
  • Reaction mixture was then cooled to 60° C and the solvents were removed in vacuo.
  • the residue was diluted with water (25 ml) and cooled to 10° C. pH of the solution was adjusted to 7.0 by adding 3N aqueous hydrochloric add (265 ml). Ethyl acetate (800 ml) was added and the pH was further lowered to 5.0 with 3N aqueous hydrochloric add. After stirring for 10 minutes at 15° C, layers were separated and aqueous layer was extraded with ethyl acetate (125 ml). Combined organic layers were diluted with methanol (250 ml) and warmed to 25-30° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé pour la fabrication de simvastatine correspondant à la formule générale (I). Celle-ci consiste à chauffer un composé, à savoir, un acide ou du sel d'ammonium du composé de Formule générale (II), dans lequel Z est H ou NH4 dans un solvant organique à une température de 130 à 140 °C.
EP02749274A 2001-05-18 2002-05-16 Procede permettant la lactonisation pour la production de simvastatine Withdrawn EP1294706A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN401CH2001 2001-05-18
INMA00000401 2001-05-18
PCT/IN2002/000122 WO2002094804A1 (fr) 2001-05-18 2002-05-16 Procede permettant la lactonisation pour la production de simvastatine

Publications (1)

Publication Number Publication Date
EP1294706A1 true EP1294706A1 (fr) 2003-03-26

Family

ID=11097002

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02749274A Withdrawn EP1294706A1 (fr) 2001-05-18 2002-05-16 Procede permettant la lactonisation pour la production de simvastatine

Country Status (6)

Country Link
EP (1) EP1294706A1 (fr)
JP (1) JP2004520445A (fr)
BG (1) BG107475A (fr)
SI (1) SI21235A (fr)
SK (1) SK702003A3 (fr)
WO (1) WO2002094804A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100423892B1 (ko) * 2001-12-03 2004-03-22 씨제이 주식회사 스타틴의 제조에 있어서 새로운 락톤화 방법
WO2005012279A1 (fr) * 2003-08-04 2005-02-10 Biocon Limited Procede de lactonisation
US7777056B2 (en) 2004-03-30 2010-08-17 Lupin Ltd. Method for manufacture of 4-hydroxy pyran-2-one derivatives
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
ES2567171T3 (es) * 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
WO2010089770A2 (fr) 2009-01-19 2010-08-12 Msn Laboratories Limited Procédé amélioré d'élaboration d'acide (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophényl)quinolin-3-yl]-3,5-dihydroxy-6(e)-heptènoïque de haute pureté, y compris ses sels pharmaceutiquement acceptables
EP2526099B1 (fr) 2010-01-18 2016-03-30 MSN Laboratories Limited Procédé amélioré pour la préparation d'intermédiaires amides et leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
ZA9810764B (en) * 1998-04-22 1999-08-13 Ranbaxy Lab Ltd An improved process of lactonization in the preparation of statins.
CA2388182A1 (fr) * 1999-10-27 2001-05-03 Merck & Co., Inc. Procede de lactonisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02094804A1 *

Also Published As

Publication number Publication date
JP2004520445A (ja) 2004-07-08
SK702003A3 (en) 2003-12-02
WO2002094804A1 (fr) 2002-11-28
SI21235A (sl) 2003-12-31
BG107475A (bg) 2004-01-30

Similar Documents

Publication Publication Date Title
US5393893A (en) Process for producing simvastatin and analogs thereof
KR100407758B1 (ko) 스타틴의 제조에 있어서 락톤화 방법
SK116597A3 (en) Key intermediates in the manufacture of simvastatine
WO2002094804A1 (fr) Procede permettant la lactonisation pour la production de simvastatine
JP2003525935A (ja) 低下したレベルの二量体不純物を伴うロバスタチン及びシンバスタチンの精製方法
JP2004520445A5 (fr)
JP2002505327A (ja) シンバスタチン及び／またはその誘導体の製造方法
US6797831B2 (en) Process for lactonization to produce simvastatin
US6825362B2 (en) Process for lactonization to produce highly pure simvastatin
JP2004520444A5 (fr)
JP3802481B2 (ja) スタチンの製造における新しいラクトン化方法
SK116797A3 (en) Process for preparing simvastatin from lovastatin or mevinolinic acid
MX2007009422A (es) Proceso para la elaboracion de simvastatina.
KR20050100267A (ko) 심바스타틴의 제조 방법
MXPA01010721A (es) Metodo para la obtencion de simvastatina a partir de lovastatina.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MEENAKSHI SUNDERAM, S.,AUROBINDO PHARMA LIMITED

Inventor name: SANAPUREDDY, J. M. R.,AUROBINDO PHARMA LIMITED

Inventor name: SONNY, SEBASTIAN,C/O AUROBINDO PHARMA LIMITED

Inventor name: RAMESH, DANDALA,C/O AUROBINDO PHARMA LIMITED

17Q First examination report despatched

Effective date: 20030723

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040705